Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in North America, Europe and Israel or involving organisations from these countries.

Total search results: 7470 | Ordered by Deal: Collaboration or Financing (ascending)
1 2 3 ... 73 74 75  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
10x Genomics–Fidelity: investment, 201804 financing round Series D totalling $50m incl existing co-investor Fidelity 2018-04-26
10x Genomics–Fidelity: investment, 201901 financing round Series D extension totalling $35m incl existing + co-investor Fidelity 2019-01-07
10x Genomics–Merck (DE): CRISPR technology, 202006 collab launch integrated solution for CRISPR research 2020-06-10
10x Genomics–Meritech Capital: investment, 201804 financing round Series D totalling $50m incl new + lead investor Meritech Capital Partners 2018-04-26
10x Genomics–Meritech Capital: investment, 201901 financing round Series D extension totalling $35m incl existing + lead investor Meritech Capital 2019-01-07
10x Genomics–Paladin Capital: investment, 201804 financing round Series D totalling $50m incl existing co-investor Paladin Capital 2018-04-26
10x Genomics–PerkinElmer: DNA sequencing technology, 201701– collab joint offering of automated NGS solutions 2017-01-09
10x Genomics–SEVERAL: investment, 201804 financing round Series D $50m led by Meritech Capital Partners 2018-04-26
10x Genomics–SEVERAL: investment, 201901 financing round Series D extension $35m led by Meritech Capital + incl Fidelity + Wells Fargo 2019-01-07
10x Genomics–SEVERAL: investment, 201908–201909 IPO $390m+$58.5m with 10m+1.5m shares common stock at $39/share Nasdaq Global Select Market 2019-08-19
10x Genomics–SEVERAL: investment, 202009 public offering $440m+$66m with 4m+600k shares Class A common stock at $110/share 2020-09-08
10x Genomics–SoftBank: investment, 201804 financing round Series D totalling $50m incl existing co-investor SoftBank Group 2018-04-26
10x Genomics–SVB: credit, 201804– debt facility $75m with Silicon Valley Bank 2018-04-26
10x Genomics–Wells Fargo: investment, 201804 financing round Series D totalling $50m incl new + co-investor Wells Fargo Strategic Capital 2018-04-26
10x Genomics–Wells Fargo: investment, 201901 financing round Series D extension totalling $35m incl existing + co-investor Wells Fargo 2019-01-07
1910 Genetics–SEVERAL: investment, 2018c seed financing round $4.1m led by Sam Altman 2018-01-01
1910 Genetics–SEVERAL: investment, 202103 financing round Series A $22m co-led by M12 + Playground Global 2021-03-23
3a-Diagnostics–XPhyto Therapeutics: investment, 202107– 202110 acqisition 100% €400k upfront + €3.5m at closing ANNOUNCED 2021-07-20
3EO Health–Harvard Univ: nucleic acid diagnostics, 202208– license ww excl from Wyss Institute for portable nucleic acid detection technology 2022-08-04
3SBio–Verseau Therapeutics: cancer immunotherapy, 201902– collab MAbs developm + excl commercialisation in Greater China €na incl $15m investment 2019-02-11
4BIO Ventures–SEVERAL: investment, 201909 first closing $50m of 4BIO Ventures II fund targeting $150m 2019-09-09
4D Lifetec–SEVERAL: investment, 202207 financing round Series B CHF1.9m first closing from existing + new investors + strategic partners 2022-07-11
4Pharma–BC Platforms: investment, 202306 acquisition €na of 4Pharma by BC Platforms 2023-06-01
4SC–SEVERAL: investment, 201706–201707 cash capital increase €41m with 11.68m new shares at €3.5/share 2017-06-12
4titude–Brooks Automation: investment, 201710 acquisition $65m in cash of 4titude Ltd by Brooks 2017-10-05
54gene–SEVERAL: investment, 201907 seed financing round $4.5m 2019-07-01
54gene–SEVERAL: investment, 202004 financing round Series A $15m led by Adjuvant Capital 2020-04-14
54gene–SEVERAL: investment, 202109 financing round Series B $25m led by Cathay AfricInvest Innovation Fund 2021-09-16
64x Bio–Fifty Years: investment, 202011 seed financing round totalling $4.5m disclosed incl co-lead investor Fifty Years 2020-11-16
64x Bio–First Round Capital: investment, 202011 seed financing round totalling $4.5m disclosed incl co-lead investor First Round Capital 2020-11-16
64x Bio–KKH Advisors: public relations, 202201 service existent by KKH Advisors 2022-01-19
64x Bio–LifeForce Capital: investment, 202201 financing round Series A totalling $55m incl new + lead investor LifeForce Capital 2022-01-19
64x Bio–Refactor Capital: investment, 202011 seed financing round totalling $4.5m disclosed incl co-lead investor Refactor Capital 2020-11-16
64x Bio–SEVERAL: investment, 202011 seed financing round $4.5m disclosed as 64x Bio emerges from stealth 2020-11-16
64x Bio–SEVERAL: investment, 202201 financing round Series A $55m led by Lifeforce Capital 2022-01-19
908 Devices–ARCH Venture: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor ARCH Ventures 2019-04-29
908 Devices–Casdin Capital: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Casdin Capital 2019-04-29
908 Devices–Manufacturing USA: grant, 201907– grant from NIIMBL for developm of at-line bioreactor process analytics tog w MilliporeSigma et al 2019-07-25
908 Devices–Northpond Ventures: investment, 201904 financing round Series E totalling $17.5m incl new + lead investor Northpond Ventures 2019-04-29
908 Devices–Razor’s Edge Ventures: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Razor’s Edge Ventures 2019-04-29
908 Devices–Sands Capital: investment, 201904 financing round Series E totalling $17.5m incl new + co-investor Sands Capital Ventures 2019-04-29
908 Devices–Sartorius: bioprocess control technology, 202106 collab product integration Rebel media analyzer with SIMCA data exploratory tool 2021-06-22
908 Devices–Saudi Arabia: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Saudi Aramco Energy Ventures 2019-04-29
908 Devices–Schlumberger: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Schlumberger 2019-04-29
908 Devices–Securecell: bioprocess control technology, 202106 collab product integration Rebel media analyzer with Lucullus PIMS 2021-06-22
908 Devices–SEVERAL: investment, 201703 financing round Series D $20m from new investors Tao Capital + Cormorant + existing investors 2017-03-15
908 Devices–SEVERAL: investment, 201904 financing round Series E $17.5m led by new investor Northpond Ventures 2019-04-29
908 Devices–SEVERAL: investment, 202012 IPO $130m+$19.5m net $136.6m with 6.5m+975k shares common stock at $20/share at Nasdaq Global Market 2020-12-18
908 Devices–SEVERAL: investment, 202111 public offering $100.8m net $94.4m with 3.15m shares common stock at $32/share 2021-11-15
908 Devices–Tao Capital: investment, 201904 financing round Series E totalling $17.5m incl existing + co-investor Tao Capital Partners 2019-04-29
A-Alpha Bio–Lux Capital: investment, 202109 financing round Series A totalling $20m incl co-investor Lux Capital 2021-09-08
A-Alpha Bio–Madrona Venture: investment, 202109 financing round Series A totalling $20m incl lead investor Madrona Venture Group 2021-09-08
A-Alpha Bio–Perceptive Advisors: investment, 202109 financing round Series A totalling $20m incl co-investor Perceptive Xontogeny Venture Fund 2021-09-08
A-Alpha Bio–SEVERAL: investment, 202109 financing round Series A $20m led by Madrona Venture Group 2021-09-08
Aadi Bioscience–Celgene: mTOR inhibitor, 2014– license for ABI-009 to Aadi Bioscience 2014-01-01
Aadi Bioscience–Helsinn: investment, 201705 financing round Series A totalling $23m incl $2m from co-investor Helsinn Investment Fund 2017-05-08
Aadi Bioscience–SEVERAL: investment, 201705 financing round Series A $23m led by Hermed Capital with Celgene + Vivo Capital + Helsinn et al 2017-05-08
AAIPharma Services–Cambridge Major Laboratories: investment, 201312 merger in late 2013 2013-12-31
Aalto Bio Reagents–Biosynth Carbosynth: investment, 202205 acquisition of Aalto by Biosynth Carbosynth 2022-05-25
AAVantgarde Bio–SEVERAL: investment, 202306 financing round Series A €61m led by Atlas Venture + Forbion 2023-06-06
AavantiBio–Bain Capital: investment, 202010 financing round Series A totalling $107m incl investor Bain Capital Life Sciences 2020-10-22
AavantiBio–Perceptive Advisors: investment, 202010 financing round Series A totalling $107m incl investor Perceptive Advisors 2020-10-22
AavantiBio–RA Capital: investment, 202010 financing round Series A totalling $107m incl investor RA Capital Management 2020-10-22
AavantiBio–Sarepta: investment, 202010 financing round Series A totalling $107m incl $15m from Sarepta Therapeutics 2020-10-22
AavantiBio–SEVERAL: investment, 202010 financing round Series A $107m from Perceptive Advisors + Bain Capital LS + RA Capital + Sarepta 2020-10-22
AB Science–RA Capital: investment, 201604 private placement €12m with 764,820 shares at €15.69/share with attached 191,205 warrants 2016-04-18
AB Science–SEVERAL: investment, 201604 private placement €12m w 765k new shares at €15.69/share 2016-04-18
AB Science–SEVERAL: investment, 201703 private placement €19m net €18.43m w 1.24m new shares at €15.3/share 2017-03-31
Abata Therapeutics–SEVERAL: investment, 202106 financing round Series A $95m led by seed investor Third Rock Ventures 2021-06-23
Abaxis–Zoetis: investment, 201805–201807 acquisition $2b for $83/share in cash 2018-05-16
AbbVie–908 Devices: sample separation technology, 201806 supply existent use of ZipChip by AbbVie 2018-06-04
AbbVie–Apogenix: TRAIL receptor agonists, 201407 aquisition of ww rights to all TRAIL receptor agonists of Apogenix by AbbVie 2014-07-01
AbbVie–Argenx: SIMPLE antibodies, 201604– collob $40m upfront + $645m milestones + royalties developm + commerc of ARGX-115 2016-04-01
AbbVie–Capsida Biotherapeutics: gene therapy, 202104– collab $80m upfront + $530m milestones + royalties capsids for 3 CNS gene therapy targets 2021-04-29
AbbVie–Frontier Medicines: E3 ligase degraders, 202012– strategic global collab $55m upfront + cost reimbursement + >1$b milestones + royalties 2020-12-02
AbbVie–Harpoon Therapeutics: cancer immunotherapy, 201710– collab research €na using TriTAC platform to discover drugs against AbbVie I-O targets 2017-10-18
AbbVie–Inventiva: pharmaceutical, 201702 collab RnD existent 2017-02-15
AbbVie–Mission Therapeutics: DUB inhibitors, 201811– collab RnD + license option €na for Alzheimer’s + Parkinson’s diseases 2018-11-15
AbbVie–Temedica: digital patient companion app, 202308 collab launch of companion app Tami for patients with chronic IBD in Germany 2023-08-02
AbbVie–Teneobio: antibody cancer drug, 201902– collab $90m upfront + milestones RnD + right to acquire TNB-383B via TeneoOne Inc 2019-02-11
AbbVie–Voyager Therapeutics: AAV technology, 201802– collab ww excl $69m upfront +>$1b milestones + royalties developm vectorised tau-Abs for AD 2018-02-20
AbbVie–Voyager Therapeutics: AAV technology, 201902– collab ww excl $65m upfront +>$1b milestones + royalties developm vectorised Abs for PD 2019-02-22
Abcam–BrickBio: antibody technology, 201911– collab use of BrickBio conjugation technology for research + diagnostic antibodies 2019-11-08
Abcam–Danaher: investment, 202308– acquisition $24/share in cash = enterprise value $5.7b incl assumed indebtedness + net of acquired cash 2023-08-28
Abcam–SEVERAL: investment, 202010 US IPO $156.5m+23.5m with 8.95m+1.34m ADSs at $17.5/ADS at Nasdaq Global Market 2020-10-19
AbCellera–DCVC: investment, 201809 financing round Series A totalling $10m incl lead investor DCVC Bio 2018-09-27
AbCellera–Harbour BioMed: drug discovery services, 201805– collab integration single-cell Ab discovery services w H2L2 transgenic mouse platform 2018-05-30
AbCellera–SEVERAL: investment, 201809 financing round Series A $10m led by DCVC Bio 2018-09-27
AbeXXa Biologics–Boehringer: investment, 201712 existent investment by BIVF 2017-12-11
ABF–Genedata: bioinformatics, 201707– supply expansion use of Genedata Selector by AB Enzymes for decision support 2017-07-11
Abide Therapeutics–Lundbeck: investment, 201905 acquisition $250m upfront + $150m milestones of Abide by Lundbeck 2019-05-06
Abingworth–Carlyle: investment, 202204–202208 acquisition €na of Abingworth by Carlyle 2022-04-11
Abingworth–Goodwin Procter: legal services, 201807 supply service legal counsel for $315m Abingworth Bioventures VII Fund 2018-07-09
Abingworth–Huntsworth: public relations, 202102 service existent by Citigate Dewe Rogerson 2021-02-03
Abingworth–SEVERAL: investment, 201807 final closing of $315m Abingworth Bioventures VII Fund 2018-07-09
Abingworth–SEVERAL: investment, 202102 final closing at $465m of Abingworth Bioventures 8 Fund 2021-02-03
Abingworth–SEVERAL: investment, 202105 final closing at $582m of Abingworth Clinical Co-Development Fund 2 2021-05-10
Abivax–Column Group: investment, 202209 reserved equity capital increase totalling €46.2m incl new + lead investor TCG X 2022-09-02
Abivax–Deep Track Capital: investment, 202209 reserved equity capital increase totalling €46.2m incl new + co-investor Deep Track Capital 2022-09-02
Abivax–Invus Group: investment, 202209 reserved equity capital increase totalling €46.2m incl co-investor Invus 2022-09-02
1 2 3 ... 73 74 75  next pagenext page



Advertisement

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture EBD Group World of Partnering Opportunities 650x300px

» top